147643-63-8

Upstream product

• 142001-92-1 N-[2-(3,4-Dichlorophenyl)-4-hydroxybutyl]-N-methylbenzamide 
• 147643-61-6 (S)-2-(3,4-dichlorophenyl)pent-4-enoic acid N-methyl amide 
• 156300-01-5 (S)-N-methyl-(2-(3,4-dichlorophenyl)pent-4-enyl)amine 
• 142001-90-9 (S)-N-[2-(3,4-Dichlorophenyl)-4-hydroxybutyl]-N-methylbenzamide 

Downstream Products

• 161609-58-1 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(2-hydroxyphenyl)piperidino]butyl]-N-methylbenzamide hydrochloride 
• 161609-68-3 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(pyridin-2-yl)piperidino]butyl]-N-methylbenzamide hydrochloride 
• 161609-60-5 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(4-hydroxyphenyl)piperidino]butyl]-N-methylbenzamide hydrochloride 
• 161609-55-8 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(2-methylsulfinylphenyl)piperidino]butyl]-N-methylbenzamide hydrochloride 
• 161609-67-2 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(2-fluoropyrid-3-yl)piperidino]butyl]-N-methylbenzamide hydrochloride 
• 161609-56-9 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(4-methylthiophenyl)piperidino]butyl]-N-methylbenzamide hydrochloride 
• 161609-59-2 (S)-N-[2-(3,4-Dichlorophenyl)-4-[4-(3-hydroxyphenyl)piperidino]butyl]-N-methylbenzamide hydrochloride 

Relevant academic research and scientific papers

NOVEL DUAL NK2/NK3-ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THEIR PREPARATIONS

The present invention relates to novel dual NK2/NK3-antagonists of formula (I) wherein the meaning of X and R1 to R5 is defined in the claims and in the description and also to pharmaceutical compositions comprising these compounds. Furthermore, the invention relates to processes for the preparation of the novel dual NK2/NK3-antagonists and to their uses.

Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation

Dual NK2/NK3-antagonists corresponding to formula I: and physiologically compatible salts of such compounds in which X and R1 to R5 have specific defined meanings, pharmaceutical compositions containing such compounds, methods of using such compounds to treat or inhibit disorders mediated by tachykinin receptors, and a process for preparing such compounds.

Design and synthesis of substituted N-methylbenzamide analogues derived from SR 48,968 as neurokinin-2 receptor antagonists

A series of N-methylbenzamide analogues (2-18) that is structurally derived from SR 48,968, a potent neurokinin-2 (NK2) receptor antagonist (pKb 9.1), has been obtained using asymmetric synthesis. Isothiocyanato-N-methylbenzamide (10-12) and bromoacetamido-N-methylbenzamide derivatives (16-18) have been designed to serve as potential electrophilic affinity labels. Nitro-N-methylbenzamide (4-6) and acetamido-N-methylbenzamide (13-15) were designed to serve as the nonelectrophilic controls for these ligands. Functional assay results using guinea pig trachea indicate that electrophilic N-methylbenzamide analogues exhibit potent but surmountable NK2 receptor antagonist activity. Several members of this series (2, 3, 7-9) exhibit potent NK2 receptor antagonist potencies with pK b values in the range of 9.1-9.7. para-Fluoro substituted analogue 3 was found to be highly potent with a pKb of 9.7.

4-Alkylpiperidines related to SR-48968: Potent antagonists of the neurokinin-2 (NK2) receptor

A series of 4-alkylpiperidine derivatives related to the potent neurokinin-2 (NK2) receptor antagonist SR-48968 (1) is described. Simple aliphatic derivatives were found to be poorly active, but appropriate placement of an alcohol functional group afforded compounds that were of similar activity to 1. Several representatives in this series, such as the 4- (1-hydroxy-1-ethylpropyl)piperidine (14), were found to exhibit oral activity in a model of labored abdominal breathing in guinea pigs. These results expand the latitude of substituents available in this region of this series of NK2 receptor antagonists.

Aryl substituted heterocycles

The present invention concerns the novel use of aryl substituted heterocycles of formula I, set out below, which antagonize the pharmacological actions of one of ent endogenous neuropeptide tachykinins an the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment. Certain novel aryl substituted heterocycles of formula I and novel intermediates for their manufacture are also provided. STR1

CARBOXAMIDE DERIVATIVES FOR TREATING ASTHMA

The present invention concerns novel carboxamide derivatives of formula I, set out hereinbelow which antagonize the pharmacological actions of one of the endogenous neuropeptide tachykinins at the neurokinin 2 (NK2) receptor, making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the novel carboxamide derivatives for use in such treatment, methods for their use, and processes and intermediates for the manufacture of the novel carboxamide derivatives. STR1

Therapeutic heterocycles which antagonize neurokinin receptors

Compounds of formula I STR1 wherein G, J, L, M, m and D have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.